No abstract available.
Tinea*

No abstract available.
Tinea Pedis* ; Tinea* ; Trichosporon*

No abstract available.
Fluconazole* ; Tinea Capitis* ; Tinea*

Background: Tinea corporis and cruris are superficial fungal infections mainly caused by dermatophytes. The antifungal effect of carica papaya latex cream has been demonstrated in clinical studies, however, larger population and comparative studies to standard antifungal agents are needed to further strengthen this conclusion. This study determined the efficacy and safety of 1.5% carica papaya latex in cream base as treatment for tinea corporis and/or cruris compared to 1% terbinafine cream. Methods: This is a randomized, double-blind controlled trial wherein subjects with a clinical diagnosis of tinea corporis or cruris confirmed by microscopy applied terbinafine or carica papaya latex cream twice daily for 6 weeks. The efficacy and safety were assessed 2, 4, and 6 weeks using clinical and mycological cure parameters. The incidence of adverse effects was likewise evaluated. Results: 90 subjects were randomized, 45 in carica papaya group and 45 in the terbinafine group. Both groups had statistically comparable improvements based on symptoms and mycological cure rates. Adverse events are significantly higher in the papaya latex cream group. Conclusion Carica papaya latex cream is as effective as terbinafine cream in the treatment of tinea corporis and/or cruris, but it has a higher incidence of adverse events.
Terbinafine ; Tinea cruris ; Tinea

No abstract available.
Psoriasis* ; Tinea Capitis* ; Tinea Favosa ; Tinea*

No abstract available.
Porokeratosis* ; Tinea*

No abstract available.
Diagnosis* ; Tinea*

No abstract available.
Simplexvirus* ; Tinea*

No abstract available.
Tinea* ; Trichophyton*

OBJECTIVE: The study aimed to assess the efficacy and safety of Senna alata (akapulko) plant extracts compared with topical antifungals in the treatment of superficial fungal skin infections.

METHODS: A systematic review and meta-analysis of randomized controlled trials that studied patients with diagnosed cutaneous tinea or dermatophytosis (excluding hair and nail), tinea versicolor, or cutaneous candidiasis, via microscopy or culture, and compared the efficacy and safety of S. alata (akapulko) extract versus topical antifungals. Two authors independently screened titles and abstracts of merged search results from electronic databases (The Cochrane Skin Group Specialized Register, CENTRAL, MEDLINE, EMBASE (January 1990 to December 2011), Health Research and Development Information Network (HERDIN), and reference lists of articles), assessed eligibility, assessed the risk of bias using the domains in the Cochrane Risk Bias tool and collected data using a pretested Data extraction form (DEF). Meta-analyses were performed when feasible.

RESULTS: We included seven RCTs in the review. There is low certainty of evidence that S. alata 50% lotion is as efficacious as sodium thiosulfate 25% lotion (RR 0.91, 95% CI, 0.79 to 1.04; 4 RCTs, n=216; p=0.15; I2=52%) and high quality evidence that S. alata cream is as efficacious as ketoconazole (RR 0.95, 95% CI, 0.82 to 1.09; 1 RCT, n=40; p=0.44) and terbinafine cream (RR 0.93, 95% CI, 0.86 to 1.01; 1 RCT, n=150; p=0.09) in mycologic cure. For adverse effects, there is very low certainty of evidence of increased harm with S. alata 50% lotion compared to sodium thiosulfate 25% lotion (RR 1.26, 95% CI, 0.46, 3.44; 2 RCTs, n=120; p=0.65; I2=19%). Adverse effects were few and mild.

CONCLUSION: S. Alata 50% lotion may be as efficacious as sodium thiosulfate 25% lotion and is as efficacious as ketoconazole 2% and terbinafine 1% creams. There is insufficient evidence to compare the safety of S. alata 50% lotion with sodium thiosulfate 25% lotion.